ATRECA INC - A (BCEL) Stock Price, Forecast & Analysis
USA - NASDAQ:BCEL - US04965G1094 - Common Stock
BCEL Key Statistics, Chart & Performance
The current stock price of BCEL is 0.15 USD. In the past month the price decreased by -51.61%. In the past year, price decreased by -87.8%.
BCEL Latest News, Press Relases and Analysis
BCEL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.14 | 386.36B | ||
| AMGN | AMGEN INC | 14.8 | 174.25B | ||
| GILD | GILEAD SCIENCES INC | 14.43 | 146.60B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.26 | 107.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.55 | 69.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 866.08 | 57.90B | ||
| INSM | INSMED INC | N/A | 40.57B | ||
| NTRA | NATERA INC | N/A | 28.36B | ||
| BIIB | BIOGEN INC | 9.33 | 22.91B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 20.53B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.89 | 14.88B |
Related stock screener links
About BCEL
Company Profile
Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. The company is headquartered in San Carlos, California and currently employs 90 full-time employees. The company went IPO on 2019-06-20. The firm is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. The company commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. The company is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
Company Info
ATRECA INC - A
835 Industrial Road,, 75 Shoreway Road, Suite C
San Carlos CALIFORNIA 94063 US
CEO: John A. Orwin
Employees: 90
Phone: 16505952595
ATRECA INC - A / BCEL FAQ
What does BCEL do?
Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. The company is headquartered in San Carlos, California and currently employs 90 full-time employees. The company went IPO on 2019-06-20. The firm is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. The company commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. The company is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
Can you provide the latest stock price for ATRECA INC - A?
The current stock price of BCEL is 0.15 USD. The price decreased by -11.76% in the last trading session.
What is the dividend status of ATRECA INC - A?
BCEL does not pay a dividend.
What is the ChartMill technical and fundamental rating of BCEL stock?
BCEL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is ATRECA INC - A (BCEL) stock traded?
BCEL stock is listed on the Nasdaq exchange.
What is the employee count for BCEL stock?
ATRECA INC - A (BCEL) currently has 90 employees.
BCEL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BCEL. When comparing the yearly performance of all stocks, BCEL is a bad performer in the overall market: 97.03% of all stocks are doing better.
BCEL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BCEL. The financial health of BCEL is average, but there are quite some concerns on its profitability.
BCEL Financial Highlights
Over the last trailing twelve months BCEL reported a non-GAAP Earnings per Share(EPS) of -1.95. The EPS increased by 29.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -371.75% | ||
| ROE | -905.28% | ||
| Debt/Equity | 0 |
BCEL Forecast & Estimates
10 analysts have analysed BCEL and the average price target is 5.61 USD. This implies a price increase of 3640% is expected in the next year compared to the current price of 0.15.